mtppi epo outcomes research presented to fda /cder joint meeting of the cardiovascular and renal...
TRANSCRIPT
![Page 1: MTPPI EPO Outcomes Research Presented to FDA /CDER Joint Meeting of the Cardiovascular and Renal Drugs & Drug Safety and Risk Management Advisory Committees](https://reader034.vdocuments.site/reader034/viewer/2022051619/56649e5c5503460f94b542e4/html5/thumbnails/1.jpg)
MTPPI EPO Outcomes Research
Presented to FDA /CDER
Joint Meeting of the Cardiovascular and Renal
Drugs & Drug Safety and Risk Management
Advisory Committees
September 11, 2007
Hilton Washington
Gaithersburg, MD 1
![Page 2: MTPPI EPO Outcomes Research Presented to FDA /CDER Joint Meeting of the Cardiovascular and Renal Drugs & Drug Safety and Risk Management Advisory Committees](https://reader034.vdocuments.site/reader034/viewer/2022051619/56649e5c5503460f94b542e4/html5/thumbnails/2.jpg)
Background and Context
Dennis CotterPresident of Medical Technology and Practice Patterns Institute (MTPPI)
4733 Bethesda Avenue #510
Bethesda, MD 20814
2
![Page 3: MTPPI EPO Outcomes Research Presented to FDA /CDER Joint Meeting of the Cardiovascular and Renal Drugs & Drug Safety and Risk Management Advisory Committees](https://reader034.vdocuments.site/reader034/viewer/2022051619/56649e5c5503460f94b542e4/html5/thumbnails/3.jpg)
Decade-long study of EPO
• Identified Medicare and non-Medicare use of EPO
• Quantified total EPO use among dialysis patients
• Currently, PI on R01 grant focusing on the role of EPO dosing and patient outcomes
3
![Page 4: MTPPI EPO Outcomes Research Presented to FDA /CDER Joint Meeting of the Cardiovascular and Renal Drugs & Drug Safety and Risk Management Advisory Committees](https://reader034.vdocuments.site/reader034/viewer/2022051619/56649e5c5503460f94b542e4/html5/thumbnails/4.jpg)
Hemoglobin values have increased steadily after EPO introduced
Source: USRDS 2006 Annual Data Report
4
![Page 5: MTPPI EPO Outcomes Research Presented to FDA /CDER Joint Meeting of the Cardiovascular and Renal Drugs & Drug Safety and Risk Management Advisory Committees](https://reader034.vdocuments.site/reader034/viewer/2022051619/56649e5c5503460f94b542e4/html5/thumbnails/5.jpg)
Widespread EPO use based on 2000 DOQI findings including:
– Survival benefits
– Decreased incidence of hospitalization
– Partial regression of left ventricular hypertrophy (LVH)
– Improved quality of life
– Increased exercise capacity
5
![Page 6: MTPPI EPO Outcomes Research Presented to FDA /CDER Joint Meeting of the Cardiovascular and Renal Drugs & Drug Safety and Risk Management Advisory Committees](https://reader034.vdocuments.site/reader034/viewer/2022051619/56649e5c5503460f94b542e4/html5/thumbnails/6.jpg)
However, survival findings might have been confounded by EPO treatment itself
6
![Page 7: MTPPI EPO Outcomes Research Presented to FDA /CDER Joint Meeting of the Cardiovascular and Renal Drugs & Drug Safety and Risk Management Advisory Committees](https://reader034.vdocuments.site/reader034/viewer/2022051619/56649e5c5503460f94b542e4/html5/thumbnails/7.jpg)
Application of causal modeling techniques
Received R01 grant (5R01DK066011-02 Epoetin Therapy and Survival of
Hemodialysis Patients) to examine the role of EPO treatment in patient outcomes
7
![Page 8: MTPPI EPO Outcomes Research Presented to FDA /CDER Joint Meeting of the Cardiovascular and Renal Drugs & Drug Safety and Risk Management Advisory Committees](https://reader034.vdocuments.site/reader034/viewer/2022051619/56649e5c5503460f94b542e4/html5/thumbnails/8.jpg)
Introduction to Causal Modeling
Miguel Hernán
Associate Professor of Epidemiology
Department of Epidemiology
Harvard School of Public Health
677 Huntington Avenue
Boston, MA 02115
8
![Page 9: MTPPI EPO Outcomes Research Presented to FDA /CDER Joint Meeting of the Cardiovascular and Renal Drugs & Drug Safety and Risk Management Advisory Committees](https://reader034.vdocuments.site/reader034/viewer/2022051619/56649e5c5503460f94b542e4/html5/thumbnails/9.jpg)
Goal
To estimate the effect of EPO on hematocrit and survival among renal failure patients with anemia
A RCT would be ideal
Next best thing is an observational study that mimics an RCT
9
![Page 10: MTPPI EPO Outcomes Research Presented to FDA /CDER Joint Meeting of the Cardiovascular and Renal Drugs & Drug Safety and Risk Management Advisory Committees](https://reader034.vdocuments.site/reader034/viewer/2022051619/56649e5c5503460f94b542e4/html5/thumbnails/10.jpg)
Problem with observational studies
Patients with worse prognosis tend to receive higher EPO doses (confounding by indication)
Not a problem in ITT analyses of RCTs
10
![Page 11: MTPPI EPO Outcomes Research Presented to FDA /CDER Joint Meeting of the Cardiovascular and Renal Drugs & Drug Safety and Risk Management Advisory Committees](https://reader034.vdocuments.site/reader034/viewer/2022051619/56649e5c5503460f94b542e4/html5/thumbnails/11.jpg)
Actually, there are 2 problems
1. Confounding may be unmeasured
2. Confounding may be measured but inappropriately adjusted for
11
![Page 12: MTPPI EPO Outcomes Research Presented to FDA /CDER Joint Meeting of the Cardiovascular and Renal Drugs & Drug Safety and Risk Management Advisory Committees](https://reader034.vdocuments.site/reader034/viewer/2022051619/56649e5c5503460f94b542e4/html5/thumbnails/12.jpg)
Problem 1Unmeasured confounding
THE fundamental problem
Need measurements of all important prognosis factors that are also indications for treatment but can never prove you have all confounders
12
![Page 13: MTPPI EPO Outcomes Research Presented to FDA /CDER Joint Meeting of the Cardiovascular and Renal Drugs & Drug Safety and Risk Management Advisory Committees](https://reader034.vdocuments.site/reader034/viewer/2022051619/56649e5c5503460f94b542e4/html5/thumbnails/13.jpg)
Problem 2Inappropriately adjusting for confounding
Conventional statistical methods cannot appropriately adjust for confounding
When the prognosis factors (e.g., hematocrit) that affect treatment decisions (e.g., EPO dose) are themselves affected by prior treatment decisions
A solvable problem: just use inverse probability weighting (IPW)
13
![Page 14: MTPPI EPO Outcomes Research Presented to FDA /CDER Joint Meeting of the Cardiovascular and Renal Drugs & Drug Safety and Risk Management Advisory Committees](https://reader034.vdocuments.site/reader034/viewer/2022051619/56649e5c5503460f94b542e4/html5/thumbnails/14.jpg)
IPW: Utility
Can be used to mimic an RCT using observational data
Under the assumption of no unmeasured confounding
Even in the presence of time-varying confounders affected by prior treatment
14
![Page 15: MTPPI EPO Outcomes Research Presented to FDA /CDER Joint Meeting of the Cardiovascular and Renal Drugs & Drug Safety and Risk Management Advisory Committees](https://reader034.vdocuments.site/reader034/viewer/2022051619/56649e5c5503460f94b542e4/html5/thumbnails/15.jpg)
IPW: Technical details
Each subject is weighted by the inverse of the estimated probability of receiving the EPO dose that he actually received
Essentially equivalent to standardization
The corresponding weighted models estimate the parameters of marginal structural models
15
![Page 16: MTPPI EPO Outcomes Research Presented to FDA /CDER Joint Meeting of the Cardiovascular and Renal Drugs & Drug Safety and Risk Management Advisory Committees](https://reader034.vdocuments.site/reader034/viewer/2022051619/56649e5c5503460f94b542e4/html5/thumbnails/16.jpg)
IPW: Examples of application
IPW extensively used in HIV/AIDS research
In fact, NIH required expertise on IPW when requesting applications for estimating the effects of antiretrovirals from observational data
IPW replicated estimates from RCTs in the HIV/AIDS field
16
![Page 17: MTPPI EPO Outcomes Research Presented to FDA /CDER Joint Meeting of the Cardiovascular and Renal Drugs & Drug Safety and Risk Management Advisory Committees](https://reader034.vdocuments.site/reader034/viewer/2022051619/56649e5c5503460f94b542e4/html5/thumbnails/17.jpg)
IPW: Our application
We used IPW to estimate the survival and mean hematocrit of subjects randomly assigned to different EPO doses
We needed IPW because hematocrit is a time-dependent confounder (predicts both EPO dose and outcome) and is affected by prior EPO dose
17
![Page 18: MTPPI EPO Outcomes Research Presented to FDA /CDER Joint Meeting of the Cardiovascular and Renal Drugs & Drug Safety and Risk Management Advisory Committees](https://reader034.vdocuments.site/reader034/viewer/2022051619/56649e5c5503460f94b542e4/html5/thumbnails/18.jpg)
Research Findings
Yi Zhang
Senior Analyst
MTPPI
18
![Page 19: MTPPI EPO Outcomes Research Presented to FDA /CDER Joint Meeting of the Cardiovascular and Renal Drugs & Drug Safety and Risk Management Advisory Committees](https://reader034.vdocuments.site/reader034/viewer/2022051619/56649e5c5503460f94b542e4/html5/thumbnails/19.jpg)
The effect of EPO dose on hematocrit response among elderly hemodialysis patients in the U.S.
Cotter D, Zhang Y, Thamer M, Kaufman J, Hernán MA.
Kidney International 2007 [in press]
19
![Page 20: MTPPI EPO Outcomes Research Presented to FDA /CDER Joint Meeting of the Cardiovascular and Renal Drugs & Drug Safety and Risk Management Advisory Committees](https://reader034.vdocuments.site/reader034/viewer/2022051619/56649e5c5503460f94b542e4/html5/thumbnails/20.jpg)
Mean monthly hemoglobin and mean EPO dose per week
Mean monthly hemoglobin & mean EPO dose per week
3
5
7
9
11
13
15
1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004
Year
Hem
og
lob
in(g
/dl)
00
02
04
06
08
10
12
14
16
18
Mean
EP
O d
ose (
in t
ho
usan
ds o
f u
nit
s)
HB
DOSE
Citation: U.S. Renal Data System, USRDS 2005 Annual Data Report: Atlas of End-Stage Renal Disease in the United States,National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2005.
Period prevalent dialysis patients with EPO claims; monthly hemoglobin includes all claims with a hematocrit value between 10 & 50; weekly EPO dose includes all claims for patients with an average number of administrations per month of =20. EPO doses adjusted for inpatient days through December, 2003; doses in January–June, 2004, are unadjusted.
20
![Page 21: MTPPI EPO Outcomes Research Presented to FDA /CDER Joint Meeting of the Cardiovascular and Renal Drugs & Drug Safety and Risk Management Advisory Committees](https://reader034.vdocuments.site/reader034/viewer/2022051619/56649e5c5503460f94b542e4/html5/thumbnails/21.jpg)
Prior research
• Dose response relationship has not been examined since Phase II trials
– Stringent patient eligibility criteria
– Limited dose
• Observational studies have shown an inverse relationship between EPO dose and hematocrit
– Confounding by indication
21
![Page 22: MTPPI EPO Outcomes Research Presented to FDA /CDER Joint Meeting of the Cardiovascular and Renal Drugs & Drug Safety and Risk Management Advisory Committees](https://reader034.vdocuments.site/reader034/viewer/2022051619/56649e5c5503460f94b542e4/html5/thumbnails/22.jpg)
Research goals
To mimic an RCT in which subjects are randomly assigned to different arms, each receiving a different EPO dose
To compare the achieved hematocrit in each arm
22
![Page 23: MTPPI EPO Outcomes Research Presented to FDA /CDER Joint Meeting of the Cardiovascular and Renal Drugs & Drug Safety and Risk Management Advisory Committees](https://reader034.vdocuments.site/reader034/viewer/2022051619/56649e5c5503460f94b542e4/html5/thumbnails/23.jpg)
Data source• United States Renal Data System (USRDS)
– administrative database on ESRD patients whose
care is covered by Medicare
– include extensive baseline and follow-up
demographic and clinical data
– outpatient EPO claims include monthly total EPO
dose and hematocrit values
– most recent USRDS data available for researchers
23
![Page 24: MTPPI EPO Outcomes Research Presented to FDA /CDER Joint Meeting of the Cardiovascular and Renal Drugs & Drug Safety and Risk Management Advisory Committees](https://reader034.vdocuments.site/reader034/viewer/2022051619/56649e5c5503460f94b542e4/html5/thumbnails/24.jpg)
Patient population• Retrospective cohort study.
• 14,001 patients who started EPO and dialysis in
2003. – >=65 years of age– had first claim with 90 days of their first ESRD service
date– had not used EPO before– did not have a kidney transplant, HIV or cancer before
starting dialysis.– were not censored during the first complete dialysis
month
24
![Page 25: MTPPI EPO Outcomes Research Presented to FDA /CDER Joint Meeting of the Cardiovascular and Renal Drugs & Drug Safety and Risk Management Advisory Committees](https://reader034.vdocuments.site/reader034/viewer/2022051619/56649e5c5503460f94b542e4/html5/thumbnails/25.jpg)
Study variables
• Censoring events
– change of dialysis modality, transplantation, 30
days after change of dialysis provider, gap in
outpatient dialysis services, or death
• Exposure: Average EPO dose in the first 3
months of dialysis
• Outcome: HCT at month 4
25
![Page 26: MTPPI EPO Outcomes Research Presented to FDA /CDER Joint Meeting of the Cardiovascular and Renal Drugs & Drug Safety and Risk Management Advisory Committees](https://reader034.vdocuments.site/reader034/viewer/2022051619/56649e5c5503460f94b542e4/html5/thumbnails/26.jpg)
Statistical methods• Estimated inverse probability weights to adjust for
measured confounders, and then fit a weighted regression model
• Constructed a dose-response curve• Each hematocrit-EPO dose point in the curve
shows the estimated average hematocrit if subjects had been randomly assigned to that EPO dose
• 95% CI were based on bootstrap techniques
26
![Page 27: MTPPI EPO Outcomes Research Presented to FDA /CDER Joint Meeting of the Cardiovascular and Renal Drugs & Drug Safety and Risk Management Advisory Committees](https://reader034.vdocuments.site/reader034/viewer/2022051619/56649e5c5503460f94b542e4/html5/thumbnails/27.jpg)
Distribution of patients by initial EPO doses
>200 u/kg 13.1%150-200 u/kg 16.0%100-150 u/kg 31.7%50-100 u/kg 29.8%< 50 u/kg 9.4%
27
![Page 28: MTPPI EPO Outcomes Research Presented to FDA /CDER Joint Meeting of the Cardiovascular and Renal Drugs & Drug Safety and Risk Management Advisory Committees](https://reader034.vdocuments.site/reader034/viewer/2022051619/56649e5c5503460f94b542e4/html5/thumbnails/28.jpg)
Distribution of patients by hematocrit group
<30% 30-<33% 33-<36% 36-<39% >=39% 0
5
10
15
20
25
30
35
Hematocrit group
Per
cent
of
patie
nts
23,400
21,000
21,100
21,500
26,000
Average EPO dose (U/week)
28
![Page 29: MTPPI EPO Outcomes Research Presented to FDA /CDER Joint Meeting of the Cardiovascular and Renal Drugs & Drug Safety and Risk Management Advisory Committees](https://reader034.vdocuments.site/reader034/viewer/2022051619/56649e5c5503460f94b542e4/html5/thumbnails/29.jpg)
4
Dose response curve and 95% confidence intervals based on MSM
2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 38 40 42 44 46 48 5032
33
34
35
36
37
38
39
40
Note: Red dots indicate FDA-recommended starting doses
Hem
atoc
rit a
t mon
th 4
(%
)
Average epoetin dose in months 1-3 (1,000 U/week)29
![Page 30: MTPPI EPO Outcomes Research Presented to FDA /CDER Joint Meeting of the Cardiovascular and Renal Drugs & Drug Safety and Risk Management Advisory Committees](https://reader034.vdocuments.site/reader034/viewer/2022051619/56649e5c5503460f94b542e4/html5/thumbnails/30.jpg)
2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 38 40 42 44 46 48 50 5232
33
34
35
36
37
38
39
40
Average epoetin dose in month 1-3 (1,000 U/week)
Hem
atoc
rit
at m
onth
4 (
%)
Dose response curve based on standard adjustment
30
![Page 31: MTPPI EPO Outcomes Research Presented to FDA /CDER Joint Meeting of the Cardiovascular and Renal Drugs & Drug Safety and Risk Management Advisory Committees](https://reader034.vdocuments.site/reader034/viewer/2022051619/56649e5c5503460f94b542e4/html5/thumbnails/31.jpg)
Study limitations
• Potential for unmeasured confounding
• Monthly HCT and EPO dose• Unobserved clinical factors (iron level, blood
pressure, nutritional status...)• EPO use in the hospital, route of EPO
administration
• Did not consider dynamic EPO dosing regimes
• Restriction of study period and population
31
![Page 32: MTPPI EPO Outcomes Research Presented to FDA /CDER Joint Meeting of the Cardiovascular and Renal Drugs & Drug Safety and Risk Management Advisory Committees](https://reader034.vdocuments.site/reader034/viewer/2022051619/56649e5c5503460f94b542e4/html5/thumbnails/32.jpg)
Conclusions
• Dose-response curve is S-shaped• HCT plateaus at 38.5% for average EPO
doses greater than 20,000 units/week• Normal HCT target might not be achievable
for dialysis population• Starting doses recommended by FDA are
appropriate and are in the linear portion of the curve
32
![Page 33: MTPPI EPO Outcomes Research Presented to FDA /CDER Joint Meeting of the Cardiovascular and Renal Drugs & Drug Safety and Risk Management Advisory Committees](https://reader034.vdocuments.site/reader034/viewer/2022051619/56649e5c5503460f94b542e4/html5/thumbnails/33.jpg)
The relationship between EPO dose and survival among hemodialysis patients
Zhang Y, Thamer, Cotter D, Kaufman J, Hernán MA
Joint Statistical Meetings 2007 [Abstract]
33
![Page 34: MTPPI EPO Outcomes Research Presented to FDA /CDER Joint Meeting of the Cardiovascular and Renal Drugs & Drug Safety and Risk Management Advisory Committees](https://reader034.vdocuments.site/reader034/viewer/2022051619/56649e5c5503460f94b542e4/html5/thumbnails/34.jpg)
Research goals
To mimic an RCT in which subjects are randomly assigned to different arms, each receiving a different average dose of EPO
To compare the survival in each arm
34
![Page 35: MTPPI EPO Outcomes Research Presented to FDA /CDER Joint Meeting of the Cardiovascular and Renal Drugs & Drug Safety and Risk Management Advisory Committees](https://reader034.vdocuments.site/reader034/viewer/2022051619/56649e5c5503460f94b542e4/html5/thumbnails/35.jpg)
Previous research
• A plethora of observational studies have shown that higher hematocrit is associated with better survival for dialysis patients
• However, results of clinical trials demonstrated that patients targeted to higher hematocrit levels did not show survival benefits– led to a recent FDA black box warning
• The EPO dose-survival relationship has not been empirically determined 35
![Page 36: MTPPI EPO Outcomes Research Presented to FDA /CDER Joint Meeting of the Cardiovascular and Renal Drugs & Drug Safety and Risk Management Advisory Committees](https://reader034.vdocuments.site/reader034/viewer/2022051619/56649e5c5503460f94b542e4/html5/thumbnails/36.jpg)
Study design
• 20,580 incident hemodialysis patients
• Eligibility criteria – Age 65 and older
– First ESRD service in 2003 – Attend freestanding facilities– Complete baseline (first 3 months of dialysis) data
• Exposure: cumulative average EPO dose
• Outcome: death during months 4-12
• Censored if change of provider/modality, or loss to follow-up 36
![Page 37: MTPPI EPO Outcomes Research Presented to FDA /CDER Joint Meeting of the Cardiovascular and Renal Drugs & Drug Safety and Risk Management Advisory Committees](https://reader034.vdocuments.site/reader034/viewer/2022051619/56649e5c5503460f94b542e4/html5/thumbnails/37.jpg)
Methods• Estimated inverse probability weights to adjust for
measured confounders, and then fit a weighted Cox model
• Constructed survival curves for each EPO dose• Each curve shows the survival if subjects had
been randomly assigned to that EPO dose
• 95% CI were based on bootstrap techniques
37
![Page 38: MTPPI EPO Outcomes Research Presented to FDA /CDER Joint Meeting of the Cardiovascular and Renal Drugs & Drug Safety and Risk Management Advisory Committees](https://reader034.vdocuments.site/reader034/viewer/2022051619/56649e5c5503460f94b542e4/html5/thumbnails/38.jpg)
Mortality hazard ratios by EPO dose (quartiles)
Table 2. Hazard ratios and 95% confidence intervals of death disaggregated by epoetin dose categories.
Cumulative epoetin dose (units/month)MSM Standard models
Unadjusted Adjusted controlling for HCT Adjusted not controlling for HCT
1.00L U1.00L U1.00LU 1.00LU0.640.58 0.691.080.97 1.201.080.971.20 1.030.921.150.760.69 0.831.321.19 1.461.241.11 1.38 1.201.071.341.050.96 1.151.781.61 1.961.491.331.67 1.501.341.69
1st quartile (<21,500)2nd quartile (21,500-36,500)3rd quartile (36,500-58,700)4th quartile (>=58,700)
Dose Quartiles (U/Mo) IPW Standard Adjustment1.00 (ref) 1.00 (ref)0.64 (0.58, 0.69) 1.08 (0.97, 1.20)0.76 (0.69, 0.83) 1.24 (1.11, 1.38)1.05 (0.96, 1.15) 1.49 (1.33, 1.67)
1st (<21,500)
2nd (21,500-36,500)3rd (36,500-58,700)4th (>=58,700)
38
![Page 39: MTPPI EPO Outcomes Research Presented to FDA /CDER Joint Meeting of the Cardiovascular and Renal Drugs & Drug Safety and Risk Management Advisory Committees](https://reader034.vdocuments.site/reader034/viewer/2022051619/56649e5c5503460f94b542e4/html5/thumbnails/39.jpg)
Mortality rate by EPO dose
Table 2. Hazard ratios and 95% confidence intervals of death disaggregated by epoetin dose categories.
Cumulative epoetin dose (units/month)MSM Standard models
Unadjusted Adjusted controlling for HCT Adjusted not controlling for HCT
1.00L U1.00L U1.00LU 1.00LU0.640.58 0.691.080.97 1.201.080.971.20 1.030.921.150.760.69 0.831.321.19 1.461.241.11 1.38 1.201.071.341.050.96 1.151.781.61 1.961.491.331.67 1.501.341.69
1st quartile (<21,500)2nd quartile (21,500-36,500)3rd quartile (36,500-58,700)4th quartile (>=58,700)
0 2.5 5 7.5 10 12.5 15 17.5 20 22.5 25 27.5 30 32.5 35 37.5 402.5
2.7
2.9
3.1
3.3
3.5
3.7
3.9
4.1
Note: Confidence intervals are forthcoming and will be shown at the FDA presentation
Haz
ard
of d
eath
(%
)
Cumulative average epoetin dose (1000 units/week)
39
![Page 40: MTPPI EPO Outcomes Research Presented to FDA /CDER Joint Meeting of the Cardiovascular and Renal Drugs & Drug Safety and Risk Management Advisory Committees](https://reader034.vdocuments.site/reader034/viewer/2022051619/56649e5c5503460f94b542e4/html5/thumbnails/40.jpg)
Survival for EPO doses based on 3 different doses
2 4 6 8 10 12 140
0.2
0.4
0.6
0.8
1
1.2
5,000U/wk
12,500 U/wk
25,000 U/wk
Month
Su
rviv
al F
un
ctio
n
40
![Page 41: MTPPI EPO Outcomes Research Presented to FDA /CDER Joint Meeting of the Cardiovascular and Renal Drugs & Drug Safety and Risk Management Advisory Committees](https://reader034.vdocuments.site/reader034/viewer/2022051619/56649e5c5503460f94b542e4/html5/thumbnails/41.jpg)
Study limitations
• Potential for unmeasured confounding as always
• Did not consider dynamic EPO dosing regimes
• One-year survival only
41
![Page 42: MTPPI EPO Outcomes Research Presented to FDA /CDER Joint Meeting of the Cardiovascular and Renal Drugs & Drug Safety and Risk Management Advisory Committees](https://reader034.vdocuments.site/reader034/viewer/2022051619/56649e5c5503460f94b542e4/html5/thumbnails/42.jpg)
Conclusions
• Lowest mortality found for average EPO doses of 8,500-15,000 units per week
• Treating all patients with higher EPO doses (>15,000 U/wk) might decrease average survival
42
![Page 43: MTPPI EPO Outcomes Research Presented to FDA /CDER Joint Meeting of the Cardiovascular and Renal Drugs & Drug Safety and Risk Management Advisory Committees](https://reader034.vdocuments.site/reader034/viewer/2022051619/56649e5c5503460f94b542e4/html5/thumbnails/43.jpg)
Relevance of research findings to FDA labeling decisions
INITIAL DOSEIn our study cohort, 61% of all incident elderly dialysis patients receivedan initial EPO dose higher than the FDA-approved 50-100 U/kg range
DOSE-RESPONSEBased on our dose-response model, a population average EPO dose higher than 12,000 U/week would result in exceeding the FDA-approved HCT target of 36%
RISKBased on our dose-survival model, a population average EPO dose higher than 15,000 U/week would result in progressively higher mortality risks
HYPORESPONSIVE PATIENTSThe risk of increased mortality is greatest among hyporesponsive patientswho receive the largest EPO doses
43Return to Cotter